Interesting Communication....What Funding and Justify Low PP Here is a copy of a post from the other board from May 28th at 11:50.
It is an email communication sent to David from poster Freedom40 the evening after the PP was announced.
Notice David questions assumption/ source of funding.....meanwhile we know Lester and David had been working on Strategic Innovation Fund weeks prior. wonder why he questioned that?
Notice he also justifies the low PP pricing by saying the stock was only 2.5 cents not long ago....
So recap....what funding you talking about man? Yeah the 8.5 cents is justified.
Nice.....real nice.
Here is some history of communication as a reference, oldest to newest - he just responded now even though the email states otherwise: Sent: Tuesday, May 26, 2020 7:41 PM To: david@vaxil-bio.com Subject: Re: Update Hi David, Thought I would touch base after today's news, to be upfront and honest very disappointing. I had assumed along with the majority of shareholders that potential funding/partnership was incoming; clearly the need for a private placement at 0.085 speaks that is not the case. I understands the need for capital, that said without any continued update on the pre-clinical work this news is not well received by the markets, stock down 15%. If the market simply knew what Vaxil was up too perhaps it would relive some pressure and gain investor confidence back. We can only assume at this stage that the lack of updates means you are on track. I do hope that is the case. Thanks for listening. From: David Goren (VXL) <david@vaxil-bio.com> Sent: May 27, 2020 12:29 AM
To: Subject: RE: Update Your comments are noted – not sure what is the source of the “assumption” of funding. In general, stock price reflects long term trends – ours was also 2.5c not long ago. When we have updates, we will issue press releases to share with everyone at the same time. Thanks David Sent: Thursday, May 28, 2020 6:32 PM To: david@vaxil-bio.com Subject: Re: Update David,